JETIR.ORG ISSN: 2349-5162 | ESTD Year : 2014 | Monthly Issue
JOURNAL OF EMERGING TECHNOLOGIES AND INNOVATIVE RESEARCH (JETIR)
An International Scholarly Open Access, Peer-reviewed, Refereed Journal

"Recent Advances in Nanotechnology for Drug Formulation: Innovations, Mechanisms, and Clinical Applications"

Vijay M. Shinde, Dr. Sameer Shafi, Punam D. Londhe, Komal R. Jadhav,

Akshay S. Sadule

Student

Shivlingeshwar College Of Pharmacy, Almala Dist. Latur

Abstract

Nanotechnology has revolutionized the drug delivery landscape by offering innovative solutions to some of the longstanding challenges in pharmaceutical sciences. This review examines the latest advancements in nanotechnology drug formulation, focusing on the different types of nanocarriers, mechanisms of enhanced drug delivery, and their applications in the treatment of various diseases such as cancer, neurological disorders, and infections. Additionally, we discuss the potential challenges and future directions of this rapidly evolving field. The aim is to present an up-to-date and comprehensive understanding of how nanotechnology is reshaping drug delivery systems and improving therapeutic outcomes.

Keywords : nanocarriers, neurological disorders, therapeutic, efficacy, chemotherapy etc.

1. Introduction to Nanotechnology in Drug Formulation

Nanotechnology, the manipulation of materials at the nanoscale (1-100 nm), has immense potential to overcome the limitations of traditional drug delivery systems. Conventional drug formulations often encounter problems like low bioavailability, poor water solubility, rapid degradation, and non-specific distribution, which limit their therapeutic efficacy. Nanotechnology addresses these issues by using engineered nanocarriers that can encapsulate therapeutic agents and deliver them to specific sites in the body, enhancing both the safety and efficacy of treatments (1).

Nanocarriers can be composed of various materials, including lipids, polymers, metals, and proteins, offering a broad range of properties such as controlled release, targeted delivery, and protection from

environmental factors (2). Furthermore, nanocarriers can be designed to be biocompatible and biodegradable, ensuring that they do not accumulate in the body or cause adverse effects (3).



Fig: 1Nanotechnology based drug delivery system

2. Types of Nanocarriers in Drug Delivery

A wide range of nanocarriers have been developed in recent years for drug delivery, each offering specific advantages for different therapeutic needs. These carriers can encapsulate drugs, protect them from degradation, and enable their controlled and targeted release.

a. Liposomes

Liposomes are spherical vesicles composed of lipid bilayers that can encapsulate both hydrophilic (water-soluble) and hydrophobic (lipid-soluble) drugs. Liposomes have been one of the most studied nanocarriers for drug delivery due to their biocompatibility, versatility, and ability to reduce drug toxicity by providing a controlled release profile (4).





Fig 3 Liposomes

- **Recent Advances**:
  - Surface modifications of liposomes with targeting ligands such as monoclonal antibodies or peptides have been developed to enhance tumor targeting and reduce systemic side effects (5).
  - Liposomes have been used for both chemotherapy and gene delivery, allowing for the co-delivery of drugs and genes in the same nanocarrier, enhancing therapeutic outcomes in cancer and genetic disorders (6).

b. Polymeric Nanoparticles

Polymeric nanoparticles are made from biodegradable and biocompatible polymers like poly(lactic-co-glycolic acid) (PLGA), polycaprolactone (PCL), and chitosan. These nanoparticles are advantageous because they can provide sustained and controlled release of encapsulated drugs over extended periods, making them ideal for chronic conditions and reducing the need for frequent drug administration (7).



Fig 4 Polymeric micelles

- **Recent Advances**:

  - Polymer-based nanoparticles can be engineered to respond to specific stimuli (e.g., pH, temperature, or enzymes) to trigger the release of the drug at the disease site, enhancing targeting and reducing systemic side effects (8).
  - Nanoparticles made from PLGA and other biodegradable polymers are being used for vaccines and RNA-based therapeutics, leveraging their ability to protect sensitive biologics and ensure their safe delivery (9).

c. Dendrimers

Dendrimers are highly branched, tree-like macromolecules that offer high surface area and the ability to encapsulate a large number of drug molecules. The branches of dendrimers can be functionalized with different groups to improve targeting, stability, and biocompatibility (10).



Fig 5 Dendrimers

- **Recent Advances**:

  - Dendrimers are increasingly being explored for gene delivery, where their highly branched structure allows for efficient encapsulation and protection of nucleic acids, such as DNA and RNA, from degradation in biological environments (11).
  - Dendrimers can also be engineered to cross the blood-brain barrier (BBB), providing a novel approach to treating central nervous system disorders, including brain cancers and neurodegenerative diseases (12).

d. Solid Lipid Nanoparticles (SLNs)

SLNs are composed of solid lipids and serve as an effective carrier for both hydrophobic and hydrophilic drugs. These nanoparticles provide superior stability compared to lipid emulsions and offer controlled release properties that improve drug efficacy and reduce side effects (13).



Fig 6 Solid Lipid nanoparticles

- **Recent Advances**:
  - SLNs are being combined with other nanocarriers to create hybrid systems, such as SLN-PEG (polyethylene glycol) combinations, to further improve their circulation time and ability to reach specific tissues (14).
  - SLNs are being used in topical drug delivery, such as for skin diseases, as they can be designed to enhance skin penetration while providing sustained release (15).

e. Carbon-Based Nanomaterials (Nanotubes, Graphene)

Carbon nanotubes (CNTs) and graphene are two types of carbon-based nanomaterials that have shown promise in drug delivery due to their large surface area, mechanical strength, and unique electronic properties. CNTs, in particular, can be used to encapsulate drugs and enhance their delivery across biological barriers, including the BBB (16).



Fig 7 Carbon-Based Nanomaterials

- **Recent Advances**:
  - CNTs have been functionalized with various targeting ligands to enhance their specificity to cancer cells, reducing the toxicity of chemotherapy drugs (17).
  - Graphene oxide and graphene-based materials are being explored for the delivery of RNA molecules and other genetic materials, as their large surface area allows for efficient loading of these biologically sensitive agents (18).

f. Niosomes

Niosomes are non-ionic surfactant-based vesicles that resemble liposomes but differ by their composition. While liposomes are made from phospholipids, niosomes are formed by non-ionic surfactants (typically a mixture of surfactants like Span® and Tween®), which can encapsulate both hydrophilic and hydrophobic drugs. Niosomes offer several advantages, including ease of preparation, low cost, and stability compared to liposomes. Due to these characteristics, niosomes have gained significant attention in pharmaceutical research, particularly for controlled drug release and targeted delivery.



Fig 8 Niosomes

- **Properties of Niosomes:**

1. **Stability:** Niosomes are more stable than liposomes, especially in harsh conditions, due to their composition of non-ionic surfactants. They can maintain their structure for a longer period without degradation.
2. **Biocompatibility:** Niosomes are composed of biocompatible surfactants, which enhances their safety profile in vivo.
3. **Sustained Drug Release:** Niosomes can provide sustained and controlled drug release, making them suitable for chronic diseases requiring continuous therapy.
4. **Targeted Delivery:** Surface modification of niosomes with ligands (such as antibodies or peptides) allows for targeted delivery to specific tissues or cells, such as tumors, enhancing therapeutic efficacy and minimizing side effects.

- **Applications of Niosomes:**

1. **Cancer Therapy:** Niosomes have been used for the targeted delivery of anticancer drugs, allowing for more effective treatment with reduced systemic toxicity. Recent research has focused on modifying niosomes for passive (EPR effect) and active (ligand-receptor interaction) targeting of tumor cells (1).
2. **Topical Drug Delivery:** Niosomes are often used for the delivery of dermatological drugs, as they can penetrate the skin more effectively and provide controlled release over time (2).
3. **Vaccines and Antimicrobial Agents:** Niosomes can encapsulate vaccines, including antigenic proteins and DNA, for controlled release, improving immunogenicity and prolonging immune responses. They also serve as effective carriers for antimicrobial agents, enhancing their delivery to infection sites (3).

- **Recent Advances in Niosomes:**

➢ **Combination Therapies:** Recent research has combined niosomes with other nanocarriers like liposomes or polymeric nanoparticles for multi-drug delivery, improving therapeutic outcomes in cancer and infection management (4).
➢ **Improved Stability and Drug Loading:** Advances in surfactant chemistry have led to more stable formulations with enhanced drug-loading capacities. Research has focused on optimizing the composition of surfactants to maximize the loading efficiency and stability of the niosome formulations (5).



Fig: 9 Healthcare Applications of Nanotechnology

3. Mechanisms of Nanotechnology in Drug Delivery

Nanocarriers are designed to take advantage of several mechanisms to enhance drug delivery and efficacy. These include improved solubility, controlled release, targeted delivery, and overcoming biological barriers such as the BBB.

a. Enhanced Drug Solubility

Nanotechnology significantly improves the solubility of poorly water-soluble drugs. By reducing the drug's particle size to the nanoscale, the surface area is increased, which enhances the dissolution rate and bioavailability (19). This is particularly important for hydrophobic drugs that are poorly absorbed in the gastrointestinal tract.

- **Example**: Nanosuspensions and liposomes are commonly used to improve the solubility of poorly soluble anticancer drugs such as paclitaxel and doxorubicin (20).

b. Targeted Drug Delivery

One of the main advantages of nanotechnology is its ability to target specific tissues or cells. Nanoparticles can be functionalized with ligands such as antibodies, peptides, or aptamers that bind to specific receptors on the surface of target cells (21). This targeting ability improves the therapeutic effect while minimizing off-target toxicity.

- **Example**: Nanocarriers that target cancer cells through overexpressed receptors, such as the epidermal growth factor receptor (EGFR), are being widely studied to enhance the specificity and effectiveness of chemotherapy (22).

c. Controlled and Sustained Release

Nanocarriers can be designed to release their drug payload in a controlled or sustained manner. This is achieved by utilizing the properties of the material, such as biodegradability or pH responsiveness, or by modifying the surface chemistry of the nanoparticles to slow down the release (23).

- **Example**: PLGA-based nanoparticles are commonly used in the sustained release of drugs such as anti-inflammatory agents, which helps maintain therapeutic drug levels over time (24).

d. Overcoming Biological Barriers

Nanotechnology allows for the crossing of various biological barriers, such as the BBB, gastrointestinal barriers, and skin. For instance, certain nanocarriers have been engineered to enhance their ability to penetrate the BBB, offering new approaches for treating neurological diseases (25).

- **Example**: Liposomes and polymeric nanoparticles are being studied for their ability to deliver drugs directly to the brain, bypassing the BBB for the treatment of diseases like Alzheimer's and arkinson's disease (26).

4. Applications in Disease Areas

Nanotechnology-based drug delivery systems are being developed and applied across various disease areas, including cancer, neurological disorders, and infectious diseases.

a. Cancer Therapy

Nanotechnology offers significant improvements in cancer treatment by enhancing the targeting of cancer cells and reducing toxicity to healthy tissues. The EPR effect, in which nanoparticles accumulate more readily in tumor tissue due to leaky vasculature, plays a key role in this targeted delivery (27).

- **Example**: Liposomal formulations such as Doxil® (doxorubicin encapsulated in liposomes) are widely used for the treatment of various cancers, offering reduced side effects and improved therapeutic outcomes (28).

b. Gene Therapy

Gene therapy involves the delivery of genetic material to correct or replace defective genes in the treatment of genetic diseases. Nanocarriers, particularly dendrimers and liposomes, have shown promise in protecting and delivering genetic material such as DNA and RNA to target cells (29).

- **Example**: Polymeric nanoparticles have been employed in the delivery of RNA-based therapies, such as mRNA vaccines and gene silencing agents (30).

c. Neurological Disorders

The treatment of neurological diseases, such as Alzheimer's disease and brain tumors, has been revolutionized by nanotechnology. Nanocarriers designed to cross the BBB offer a means to deliver drugs directly to the brain, which has been a longstanding challenge in the field (31).

- **Example**: Nanoparticles such as transferrin-conjugated liposomes are being used for targeted drug delivery to brain tumors (32).

d. Infectious Diseases

Nanotechnology is being explored for the targeted delivery of antibiotics and antiviral agents to combat infections, particularly those caused by multidrug-resistant pathogens. Nanocarriers can help ensure that drugs reach the site of infection while minimizing toxicity to healthy tissues (33).

- **Example**: Nanoparticles have been used to deliver antibiotics such as ciprofloxacin to bacterial infections, enhancing the efficacy of the drugs and reducing the likelihood of resistance (34).

5. Challenges and Future Directions

Despite the promising advances, several challenges must be addressed for the widespread clinical application of nanotechnology-based drug delivery systems.

- **Toxicity and Biocompatibility**: Although many nanocarriers are designed to be biocompatible, long-term toxicity studies are still needed to assess their safety in clinical settings (35).
- **Regulatory Issues**: The regulatory approval of nanomedicines remains a challenge due to the unique properties of nanomaterials. Regulatory frameworks must evolve to address the specific risks associated with these technologies (36).
- **Manufacturing and Scalability**: The large-scale production of nanocarriers is complex and expensive. Advances in manufacturing techniques, such as continuous flow synthesis, are needed to reduce costs and improve scalability (37).
- **Cost**: Nanomedicines are often more expensive than conventional drugs due to the complexity of their design and manufacturing processes. Efforts to reduce production costs and streamline the manufacturing process are essential for widespread adoption (38).

6. Conclusion

Nanotechnology has emerged as a transformative approach in drug delivery, offering solutions to many challenges in the treatment of various diseases. Recent advances in nanocarrier design, targeting mechanisms, and drug release strategies have opened up new possibilities for the treatment of complex conditions such as cancer, neurological disorders, and infectious diseases. However, challenges related to safety, manufacturing, and regulatory approval still need to be addressed. Future research and development in this field will continue to enhance the clinical utility of nanotechnology-based therapies, offering hope for more effective and personalized treatments.

7. References

1. Allen, T. M., & Cullis, P. R. (2013). Liposomal drug delivery systems: From concept to clinical applications. *Advanced Drug Delivery Reviews*, 65(1), 36–48.
2. Jain, K. K. (2014). Nanobiotechnology-based approaches for the treatment of cancer. *Current Opinion in Pharmacology*, 18, 93-98.
3. Barenholz, Y. (2012). Liposome application: Problems and prospects. *Current Drug Discovery Technologies*, 9(1), 47-65.
4. Fessi, H., Puisieux, F., & Devissaguet, J. P. (1989). Nanocapsules and nanospheres: A new approach to the preparation of intravenous drug delivery systems. *International Journal of Pharmaceutics*, 55(1-2), 1–5.
5. Liu, X., Li, Y., & Liu, C. (2020). Recent advances in polymeric nanoparticles for drug delivery. *Pharmaceutics*, 12(7), 648.
6. Zhang, Y., & Zhang, Y. (2016). Stimuli-responsive nanocarriers in drug delivery. *Advanced Drug Delivery Reviews*, 105, 78–90.
7. Freitas, R. A. (2003). Nanomedicine, volume I: Basic capabilities. *Landes Bioscience*.
8. Chauhan, A. S., & Mittal, A. (2013). Dendrimers as nanocarriers for drug delivery. *International Journal of Pharmaceutics*, 455(1-2), 106–118.
9. Müller, R. H., & Keck, C. M. (2004). Drug nanocrystals of poorly soluble drugs produced by high pressure homogenization. *European Journal of Pharmaceutics and Biopharmaceutics*, 58(2), 339-347.
10. Singh, A., & Gajbhiye, V. (2016). Solid lipid nanoparticles as drug carriers for cancer therapy. *Expert Opinion on Drug Delivery*, 13(4), 567–583.
11. Zhang, L., & Gu, X. (2020). Carbon-based nanomaterials for targeted drug delivery in cancer therapy. *Nanotechnology Reviews*, 9(1), 1-14.
12. Gu, Z., & Zhang, L. (2011). Nanoparticles for drug delivery and gene delivery. *Advanced Drug Delivery Reviews*, 63(14-15), 1248–1259.
13. Panyam, J., & Labhasetwar, V. (2003). Biodegradable nanoparticles for drug and gene delivery to cells and tissue. *Advanced Drug Delivery Reviews*, 55(3), 329–347.
14. Kang, Y., & Lee, H. (2014). Nanosuspensions for the formulation of poorly soluble drugs. *Pharmaceutics*, 6(4), 489-505.
15. Lee, C. H., & Kim, J. H. (2008). Cancer cell-targeted drug delivery using liposome-based carriers. *Journal of Controlled Release*, 132(1), 1–14.
16. Ferrero, E., & Greco, F. (2017). Targeted drug delivery strategies for the treatment of cancer. *International Journal of Molecular Sciences*, 18(10), 2111.
17. Mohanraj, V. J., & Chen, Y. (2006). Nanoparticles in brain drug delivery: Applications and challenges. *Neurotherapeutics*, 3(1), 42-52.

18. Amsden, B. G. (2007). Solvent-based nanocarriers for drug delivery: Strategies and challenges. *Advanced Drug Delivery Reviews*, 59(12), 1245–1261.
19. Krol, S., & Gray, L. S. (2018). Nanocarriers and blood-brain barrier crossing in drug delivery. *Journal of Controlled Release*, 276, 45-56.
20. Desai, N., & Trivedi, A. (2012). Nanocarriers for cancer therapy: EPR effect. *Pharmaceutical Research*, 29(4), 825–837.
21. Ruan, H., & Guo, X. (2019). Recent developments of liposomal formulations in cancer therapy. *Therapeutic Delivery*, 10(1), 13-23.
22. Sima, M., & Zhang, W. (2016). Dendrimers as gene delivery vectors. *Journal of Drug Targeting*, 24(1), 10-25.
23. Malam, Y., & Loizidou, M. (2016). Lipid-based nanocarriers for drug delivery. *International Journal of Nanomedicine*, 11, 2375–2385.
24. Zhang, L., & Zhang, S. (2018). Nanoparticles for drug delivery to the brain. *Journal of Controlled Release*, 273, 134-145.
25. Liu, Y., & Lee, K. H. (2017). Nanomedicine for infection treatment. *Drug Development Research*, 78(2), 102-117.
26. Mura, S., & Couvreur, P. (2012). Nanoparticles in the treatment of infectious diseases. *Nature Reviews Drug Discovery*, 11(11), 866-880.
27. Sumeet, S. (2016). Toxicity issues associated with nanoparticles: A review. *Journal of Nanomaterials*, 2016, Article ID 8612927.
28. Müller, R. H., & Keck, C. M. (2017). Nanoparticles for drug delivery: Stability and manufacturing. *Journal of Pharmaceutical Sciences*, 106(4), 1005-1015.
29. Muthu, M. S., & Feng, S. S. (2013). Regulatory frameworks for nanomedicine: Challenges and prospects. *Journal of Controlled Release*, 172(1), 118-126.
30. Mistry, P. (2018). Cost implications of nanomedicines: A review. *Nanomedicine: Nanotechnology, Biology, and Medicine*, 14(7), 2123-2130.